AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolioAstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma). Both medicines are delivered via the Genuair device and used for the treatment of patients with chronic obstructive pulmonary disease (COPD). The agreement will ensure continued patient access to these established medicines. Covis Pharma previously